These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 33960145)

  • 1. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
    Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
    Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis.
    Yu G; Shen Y; Xu X; Zhong F
    PLoS One; 2020; 15(11):e0242982. PubMed ID: 33253313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
    Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Anlotinib in EGFR-Positive Patients with Advanced Lung Adenocarcinoma Compared with Chemotherapy: A Retrospective Study.
    Cai C; Shen Q; Shao J; Qu J; Zhou S; Zhou J
    Technol Cancer Res Treat; 2024; 23():15330338241279111. PubMed ID: 39175430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy and safety of anlotinib monotherapy or anlotinib plus immune checkpoint inhibitor for advanced small cell lung cancer with brain metastases.
    Xu M; Shao K; Wang Y; Hao Y; Song Z
    Clin Transl Oncol; 2024 Jul; 26(7):1687-1695. PubMed ID: 38363527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anlotinib-containing regimen for advanced small-cell lung cancer: A protocol of meta-analysis.
    Yu G; Cai Q; Xu X; Shen Y; Xu K
    PLoS One; 2021; 16(3):e0247494. PubMed ID: 33705427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancer.
    Ying X; Shi Z; Shao R; You G; Song Z
    Neoplasma; 2024 Jun; 71(3):297-305. PubMed ID: 38958712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib.
    Chen D; Xu J; Zhao Y; Chu T; Zhong H; Han B; Zhong R
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):401-406. PubMed ID: 31691871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study.
    Yin X; Liu X; Ren F; Meng X
    Cancer Immunol Immunother; 2024 May; 73(7):134. PubMed ID: 38758372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of anlotinib in patients with small-cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study.
    Liu Y; Cheng Y; Wang Q; Li K; Shi J; Wu L; Han B; Chen G; He J; Wang J; Qin H; Li X
    Thorac Cancer; 2021 Nov; 12(22):3039-3045. PubMed ID: 34596367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer.
    Gao X; Peng L; Zhang L; Huang K; Yi C; Li B; Meng X; Li J
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2661-2671. PubMed ID: 34748028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
    Zhou M; Chen X; Zhang H; Xia L; Tong X; Zou L; Hao R; Pan J; Zhao X; Chen D; Song Y; Qi Y; Tang L; Liu Z; Gao R; Shi Y; Yang Z
    Cancer Commun (Lond); 2019 Jun; 39(1):36. PubMed ID: 31221221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial.
    Pu X; Xiao Z; Li J; Wu Z; Ma Z; Weng J; Xiao M; Chen Y; Cao Y; Cao P; Wang Q; Xu Y; Li K; Chen B; Xu F; Liu L; Kong Y; Zhang H; Duan H; Wu L
    Lung Cancer; 2024 May; 191():107538. PubMed ID: 38552544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of anlotinib plus anti-PD-1 agents in patients with refractory advanced biliary tract cancers.
    An T; Hui Q; Zong H; Liu L; Cao X; Li R; Hu S; Liu Y; Li J; Zhao R
    Clin Transl Oncol; 2024 Aug; 26(8):2006-2019. PubMed ID: 38530557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study.
    Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D
    Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anlotinib plus oral fluoropyrimidine S-1 in refractory or relapsed small-cell lung cancer (SALTER TRIAL): a multicenter, single-arm, phase II trial.
    Wang W; Wu G; Luo W; Lin L; Zhou C; Yao G; Chen M; Wu X; Chen Z; Ye J; Yang H; Lv D
    BMC Cancer; 2024 Sep; 24(1):1182. PubMed ID: 39333988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial.
    Han X; Guo J; Li L; Huang Y; Meng X; Wang L; Zhu H; Meng X; Shao Q; Li X; Zhang Y; Wang J; Chen Y; Zhang Y; Chen Y; Zhu C; Wang Z
    Signal Transduct Target Ther; 2024 Sep; 9(1):241. PubMed ID: 39278918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of anlotinib for subsequent line treatment of small cell lung cancer: a systematic review and meta-analysis.
    Xu H; Cao D; Jie F; He A; Ge W
    Tumori; 2023 Apr; 109(2):203-214. PubMed ID: 35509221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.
    Zhang X; Zeng L; Li Y; Xu Q; Yang H; Lizaso A; Mao X; Jin R; Zeng Y; Li Q; Wang J; Li Y; Zhang Y; Yang N
    Cancer Immunol Immunother; 2021 Sep; 70(9):2517-2528. PubMed ID: 33566148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study.
    Liu J; Deng YT; Jiang Y
    Invest New Drugs; 2021 Apr; 39(2):330-336. PubMed ID: 32974853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.